Companies › Jemincare
6 active drug programs in 7 registered trials: 4 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JYB1904 | – | Phase 3 | Chronic Spontaneous Urticaria | Jun 2027 |
| JMKX003142 | – | Phase 2 | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Feb 2027 |
| JMKX000197 Injection | – | Phase 1 | Malignant Pleural Effusions (Mpe) | Nov 2026 |
| JMKX003948 | – | Phase 1 | Renal Cell Carcinoma Metastatic | Apr 2027 |
| JMKX001899 KRAS G12C inhibitor | – | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Dec 2027 |
| JMKX005425 | – | Phase 1 | Advanced Solid Tumors | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06509334 | JYB1904 | Phase 2 | Chronic Spontaneous Urticaria | Immunology | Jul 2026 |
| NCT06740019 | JMKX000197 Injection | Phase 1 | Malignant Pleural Effusions (Mpe) | Oncology | Nov 2026 |
| NCT06800651 | JMKX003142 | Phase 2 | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Genitourinary | Feb 2027 |
| NCT06321250 | JMKX003948 | Phase 1 | Renal Cell Carcinoma Metastatic | Oncology | Apr 2027 |
| NCT07402213 | JYB1904 | Phase 3 | Chronic Spontaneous Urticaria | Immunology | Jun 2027 |
| NCT06946927 | JMKX001899 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Dec 2027 |
| NCT07208136 | JMKX005425 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
No annotated target.
–
Jacobio Pharmaceuticals DualityBio Bio-Thera Solutions InSilico Medicine Hong Kong Nanjing Sanhome Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.